» Articles » PMID: 28939925

Ocular Adnexal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2017 Sep 24
PMID 28939925
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Ocular adnexal lymphomas are a group of heterogeneous neoplasms representing approximately 1-2% of non-Hodgkin lymphomas and 8% of extranodal lymphomas. The incidence of primary ocular adnexal lymphoid tumors has raised over the last decades, and this could be probably attributed to the more sophisticated diagnostic techniques. Due to the wide spectrum of clinical manifestations, ocular tissue biopsy is important in order to set a precise diagnosis based on histological, immunophenotypical and, in some cases, molecular findings. The most common subtype, which may account for up to 80% of primary ocular adnexal lymphomas, is extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue. This lymphoma is usually asymptomatic in the early phase of the disease causing a delay in the final diagnosis and prompt therapy. The pathogenesis of a proportion of these tumors has been linked to chronic inflammatory stimulation from specific infectious factors (e.g., Chlamydia psittaci) or to autoimmunity. The further improvement in diagnostic methods and the further understanding of the pathogenesis of ocular adnexal EMZL may contribute to the establishment of a more successful multidisciplinary therapeutic planning.

Citing Articles

Safety and efficacy of intralesional rituximab injection versus involved site radiation therapy in primary ocular adnexal MALT lymphoma: study protocol for a multicentre randomised controlled trial.

Liu Y, Gao Y, Jin L, Li Q, Wang X, Wu Y BMJ Open. 2024; 14(11):e084904.

PMID: 39608989 PMC: 11603821. DOI: 10.1136/bmjopen-2024-084904.


Declining incidence and improving survival of ocular and orbital lymphomas in the US between 1995 and 2018.

Alfaar A, Yousef Y, Wilson M, Hassanain O, Kakkassery V, Moustafa M Sci Rep. 2024; 14(1):7886.

PMID: 38570585 PMC: 10991268. DOI: 10.1038/s41598-024-58508-7.


The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma.

Gergely L, Udvardy M, Illes A Biomedicines. 2024; 12(3).

PMID: 38540261 PMC: 10967989. DOI: 10.3390/biomedicines12030648.


Predicting the prognosis of primary orbital lymphoma by clinical characteristics and imaging features.

Zhu J, Li B, Zhang H, Wang N Int J Ophthalmol. 2023; 16(5):705-711.

PMID: 37206183 PMC: 10172095. DOI: 10.18240/ijo.2023.05.06.


Radiation therapy for primary orbital and ocular adnexal lymphoma.

Pereira-Da Silva M, Nicola M, Altomare F, Xu W, Tsang R, Laperriere N Clin Transl Radiat Oncol. 2022; 38:15-20.

PMID: 36353653 PMC: 9637715. DOI: 10.1016/j.ctro.2022.10.001.


References
1.
Valenzuela A, Allen C, Grimes D, Wong D, Sullivan T . Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease. Ophthalmology. 2006; 113(12):2331-7. DOI: 10.1016/j.ophtha.2006.05.059. View

2.
Morgensztern D, Rosado M, Serafini A, Lossos I . Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab. Leuk Lymphoma. 2004; 45(6):1275-8. DOI: 10.1080/10428190310001641233. View

3.
Goodlad J, Davidson M, Hollowood K, Ling C, MacKenzie C, Christie I . Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000; 24(9):1279-85. DOI: 10.1097/00000478-200009000-00012. View

4.
Kiesewetter B, Raderer M . Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood. 2013; 122(8):1350-7. DOI: 10.1182/blood-2013-02-486522. View

5.
Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S . Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. Ann Hematol. 2007; 86(8):565-8. DOI: 10.1007/s00277-007-0301-y. View